RB1 and cancer: Through enterprise-wide clinical application of broad tNGS using Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT; refs. 5, 6), integrated with expression-based analysis, we identified 20 patients with SCLC whose tumors lacked RB1 and TP53 co-inactivation.